These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 34523888)
21. Neglected parasitic infections in the United States: needs and opportunities. Parise ME; Hotez PJ; Slutsker L Am J Trop Med Hyg; 2014 May; 90(5):783-785. PubMed ID: 24808243 [No Abstract] [Full Text] [Related]
22. Chagas Disease in the United States: a Public Health Approach. Bern C; Messenger LA; Whitman JD; Maguire JH Clin Microbiol Rev; 2019 Dec; 33(1):. PubMed ID: 31776135 [No Abstract] [Full Text] [Related]
23. Natural History of Treated Subarachnoid Neurocysticercosis. Nash TE; O'Connell EM; Hammoud DA; Wetzler L; Ware JM; Mahanty S Am J Trop Med Hyg; 2020 Jan; 102(1):78-89. PubMed ID: 31642423 [TBL] [Abstract][Full Text] [Related]
24. Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). White AC; Coyle CM; Rajshekhar V; Singh G; Hauser WA; Mohanty A; Garcia HH; Nash TE Clin Infect Dis; 2018 Apr; 66(8):e49-e75. PubMed ID: 29481580 [No Abstract] [Full Text] [Related]
25. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Maldonado YA; Read JS; Pediatrics; 2017 Feb; 139(2):. PubMed ID: 28138010 [No Abstract] [Full Text] [Related]
26. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Garcia HH; Gonzales I; Lescano AG; Bustos JA; Pretell EJ; Saavedra H; Nash TE; Epilepsia; 2014 Sep; 55(9):1452-9. PubMed ID: 25092547 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Garcia HH; Gonzales I; Lescano AG; Bustos JA; Zimic M; Escalante D; Saavedra H; Gavidia M; Rodriguez L; Najar E; Umeres H; Pretell EJ; Lancet Infect Dis; 2014 Aug; 14(8):687-695. PubMed ID: 24999157 [TBL] [Abstract][Full Text] [Related]
29. Risk factors for Toxoplasma gondii infection in the United States. Jones JL; Dargelas V; Roberts J; Press C; Remington JS; Montoya JG Clin Infect Dis; 2009 Sep; 49(6):878-84. PubMed ID: 19663709 [TBL] [Abstract][Full Text] [Related]
30. An estimate of the burden of Chagas disease in the United States. Bern C; Montgomery SP Clin Infect Dis; 2009 Sep; 49(5):e52-4. PubMed ID: 19640226 [TBL] [Abstract][Full Text] [Related]
31. Evaluation and treatment of chagas disease in the United States: a systematic review. Bern C; Montgomery SP; Herwaldt BL; Rassi A; Marin-Neto JA; Dantas RO; Maguire JH; Acquatella H; Morillo C; Kirchhoff LV; Gilman RH; Reyes PA; Salvatella R; Moore AC JAMA; 2007 Nov; 298(18):2171-81. PubMed ID: 18000201 [TBL] [Abstract][Full Text] [Related]
32. Deaths from cysticercosis, United States. Sorvillo FJ; DeGiorgio C; Waterman SH Emerg Infect Dis; 2007 Feb; 13(2):230-5. PubMed ID: 17479884 [TBL] [Abstract][Full Text] [Related]
33. Toxoplasma gondii infection in the United States, 1999-2000. Jones JL; Kruszon-Moran D; Wilson M Emerg Infect Dis; 2003 Nov; 9(11):1371-4. PubMed ID: 14718078 [TBL] [Abstract][Full Text] [Related]
34. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Holland GN Am J Ophthalmol; 2003 Dec; 136(6):973-88. PubMed ID: 14644206 [TBL] [Abstract][Full Text] [Related]